<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287715</url>
  </required_header>
  <id_info>
    <org_study_id>NR 10-1-203</org_study_id>
    <nct_id>NCT01287715</nct_id>
  </id_info>
  <brief_title>Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis</brief_title>
  <acronym>ABC-STOP</acronym>
  <official_title>When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Arthritis Association</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether etanercept can be withdrawn successfully
      (i.e. no occurrence of flares) in juvenile idiopathic arthritis (JIA) patients in whom
      disease remission is reached.

      Goals:

        1. to investigate in a randomized controlled trial:

             -  which proportion of JIA patients in remission can successfully discontinue
                etanercept compared to JIA patients in remission who continue etanercept;

             -  if time in remission on etanercept is an important factor in retaining remission
                after discontinuation of etanercept.

        2. to investigate in alle JIA patients who discontinue etanercept (including the control
           group):

             -  predicting factors (patient or disease characteristics, including time in
                remission, and MRP8/MRP14) for successfully discontinuation of etanercept;

             -  the disease course after discontinuation of etanercept (time to flare) and the
                effect of restarting etanercept after flaring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Juvenile Idiopathic Arthritis (JIA) is the most common cause of chronic arthritis in
      children. Etanercept has proven to be an effective treatment for JIA. Considering the risk of
      occurrence of long-term side-effects and to prevent the burden of the weekly injections and
      costs, it is a logical step to discontinue etanercept after reaching remission (no disease
      activity for at least six months). Especially since there are concerns about the long-term
      effect of suppressing the immune system with etanercept. However, little is known about if
      successful discontinuation is possible or when to stop. Risk is that the disease might flare
      (reactivate) again.

      For this study, JIA patients in remission will be selected from the ABC-register (an
      observational study including all Dutch JIA patients who use etanercept). Eligible patients
      will be randomized to stop etanercept or continue it for another 9 months. Patients are
      followed with standard visits evaluating disease activity until 12 months after
      discontinuation of etanercept. In case of a disease flare etanercept therapy will be
      reintroduced immediately and the patient will be treated according to the insight of their
      treating physician. Expected is that JIA patients who were in remission for more than 12
      months before discontinuation have a better chance to retain remission.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flare-rate</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate if the flare-rate is different between the 2 arms (continuation and discontinuation of etanercept).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of remission before withdrawal of etanercept</measure>
    <time_frame>9 months</time_frame>
    <description>To evaluate between the 2 arms (continuation and discontinuation of etanercept) if time in remission on etanercept is an important factor in retaining remission after discontinuation of etanercept.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors for successful discontinuation of etanercept</measure>
    <time_frame>12 months after discontinuation of etanercept</time_frame>
    <description>Evaluation of predictors (patient or disease characteristics, including time in remission, and MRP8/MRP14) for successful discontinuation of etanercept in all JIA patient who discontinue etanercept.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease course after flaring</measure>
    <time_frame>6 months after flare</time_frame>
    <description>After a flare (exacerbation) occurs: evaluation of time to flare and the effect of restarting etanercept after flaring.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>STOP-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinuation of etanercept</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL-arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)</description>
    <arm_group_label>STOP-arm</arm_group_label>
    <other_name>enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etanercept</intervention_name>
    <description>Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.</description>
    <arm_group_label>CONTROL-arm</arm_group_label>
    <other_name>enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Juvenile Idiopathic Arthritis (all subtypes) by the International League
             of Associations of Rheumatology (ILAR) criteria

          -  On etanercept therapy

          -  No MTX or low dose MTX (maximum 10 mg/m2)

          -  3 or more months in remission according to the criteria of Wallace (i.e. 9 or more
             months of inactive disease)

          -  Age â‰¥4 and &lt;18 years at start of study

          -  Written informed consent from parents and patients 12 years and over

        Exclusion Criteria:

          -  Systemic corticosteroids (up to 9 months prior to inclusion)

          -  Intra-articular corticosteroids (up to 6 months prior to inclusion)

          -  Synthetic DMARDs besides low dose MTX (up to 9 months prior to inclusion)

          -  Biologic DMARDs besides etanercept (up to 9 months prior to inclusion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LWA van Suijlekom-Smit, MD,PhD,MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LWA van Suijlekom-Smit, MD,PhD,MSCE</last_name>
    <phone>+31-10-7036146</phone>
    <email>l.vansuijlekom@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MH Otten, MD</last_name>
    <phone>+31-10-7036778</phone>
    <email>m.otten@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Centre Emma Children's Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MAJ van Rossum, MD, PhD</last_name>
      <email>m.a.vanrossum@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>MAJ van Rossum, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reade Institute Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MAJ van Rossum, MD, PhD</last_name>
      <email>m.a.vanrossum@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>MAJ van Rossum, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint-Lucas Andreas Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>W Armbrust, MD, PhD</last_name>
      <email>w.armbrust@bkk.umcg.nl</email>
    </contact>
    <investigator>
      <last_name>W Armbrust, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R ten Cate, MD, PhD</last_name>
      <email>r.tencate@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>R ten Cate, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SL Gorter, MD, PhD</last_name>
      <email>sgo@sint.azm.nl</email>
    </contact>
    <investigator>
      <last_name>SL Gorter, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Maartenskliniek</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>EPAH Hoppenreijs, MD, PhD</last_name>
      <email>e.hoppenreijs@cukz.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>EPAH Hoppenreijs, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LWA van Suijlekom-Smit, MD,PhD,MSCE</last_name>
      <email>l.vansuijlekom@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>LWA van Suijlekom-Smit, MD,PhD,MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haga Hospital, Juliana Children's Hospital</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Y Koopman, MD</last_name>
      <email>y.koopman@hagaziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Y Koopman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Utrecht Medical Centre Wilhelmina Children's Hospital</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R van Royen, MD, PhD</last_name>
      <email>a.vanroyen@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>A van Royen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>January 31, 2011</last_update_submitted>
  <last_update_submitted_qc>January 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>L.W.A. van Suijlekom-Smit, MD, PhD, MSCE</name_title>
    <organization>Erasmus Medical Center Sophia Children's Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

